XML 21 R11.htm IDEA: XBRL DOCUMENT
v3.22.2

Financial Instruments | 6 Months Ended
--- | ---
Jun. 30, 2022
Investments, Debt and Equity Securities [Abstract] |
Financial Instruments | Financial Instruments Cash equivalents and marketable securities are recorded at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase the comparability of fair value measures, the following hierarchy prioritizes the inputs to valuation methodologies used to measure fair value. •Level 1—Valuations based on quoted prices in active markets for identical assets or liabilities. •Level 2—Valuations based on quoted prices for similar assets and liabilities in active markets or inputs that are observable for the assets or liabilities, either directly or indirectly through market corroboration. •Level 3—Valuations based on unobservable inputs reflecting our own assumptions used to measure assets and liabilities at fair value. These valuations require significant judgment. The following table summarizes, by major security type, our restricted cash, cash equivalents, and marketable securities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):
| June 30, 2022 |  | December 31, 2021
| Amortized Cost |  | Unrealized Gains |  | Unrealized Losses |  | Fair Value |  | Fair Value
Level 1: |  |  |  |  |  |  |  |  |
Restricted cash: |  |  |  |  |  |  |  |  |
Restricted cash | $ | 10,755 |  |  | $ | — |  |  | $ | — |  |  | $ | 10,755 |  |  | $ | 10,823 |
Total restricted cash | $ | 10,755 |  |  | $ | — |  |  | $ | — |  |  | $ | 10,755 |  |  | $ | 10,823 |
Level 1 securities: |  |  |  |  |  |  |  |  |
Cash equivalents: |  |  |  |  |  |  |  |  |
Money market funds | $ | 166,174 |  |  | $ | — |  |  | $ | — |  |  | $ | 166,174 |  |  | $ | 73,138 |
Total cash equivalents | $ | 166,174 |  |  | $ | — |  |  | $ | — |  |  | $ | 166,174 |  |  | $ | 73,138 |
Level 2 securities: |  |  |  |  |  |  |  |  |
Marketable securities: |  |  |  |  |  |  |  |  |
Commercial paper | $ | 127,113 |  |  | $ | — |  |  | $ | — |  |  | $ | 127,113 |  |  | $ | 59,792 |
Asset-backed securities | 28,317 |  |  | — |  |  | (90) |  |  | 28,227 |  |  | 40,942 |
Corporate bonds | 208,362 |  |  | — |  |  | (3,465) |  |  | 204,897 |  |  | 237,402 |
U.S. treasury securities | 181,344 |  |  | — |  |  | (2,164) |  |  | 179,180 |  |  | 272,300 |
Supranational bonds | 53,027 |  |  | — |  |  | (969) |  |  | 52,058 |  |  | 70,887 |
Total marketable securities | $ | 598,163 |  |  | $ | — |  |  | $ | (6,688) |  |  | $ | 591,475 |  |  | $ | 681,323 |
We do not intend to sell any of the securities in an unrealized loss position and we expect to realize the full value of all these investments, which may be upon maturity. We did not recognize any credit losses related to our available-for-sale debt securities during the three and six months ended June 30, 2022 and 2021. The following table summarizes the amortized cost and fair value of our marketable securities as of June 30, 2022, by contractual years to maturity (in thousands):
| Amortized Cost |  | Fair Value
Due within one year | $ | 542,211 |  |  | $ | 537,242 |
Due between one and two years | 55,952 |  |  | 54,233 |
Total | $ | 598,163 |  |  | $ | 591,475 |
There were no material realized or unrealized gains or losses, either individually or in the aggregate, during the three and six months ended June 30, 2022 and 2021. Nonrecurring Fair Value Measurements We hold equity investments in certain unconsolidated entities without a readily determinable fair value. These strategic investments represent less than a 20% ownership interest in each of the entities, and we do not have significant influence over or control of the entities. We elected the practical expedient in Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 321, Investments-Equity Securities, and measure these investments at cost less any impairment, adjusted for observable price changes, if any. As of June 30, 2022, the equity investments totaled $15.6 million.

X
- References No definition available. + Details
Name: | us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for investments in certain debt and equity securities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 320 -URI https://asc.fasb.org/subtopic&trid=2209399 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 320 -URI https://asc.fasb.org/subtopic&trid=2324412 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -URI https://asc.fasb.org/topic&trid=2196928 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 940 -SubTopic 320 -URI https://asc.fasb.org/subtopic&trid=2176304 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher SEC -Name Regulation S-K (SK) -Number 229 -Section 1403 -Paragraph (b) + Details
Name: | us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration